Tango Therapeutics, Inc. Segment Reporting Other Item Amount
Tango Therapeutics, Inc. (TNGX) reported Segment Reporting Other Item Amount of $18.14 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Segment Reporting
us-gaap:SegmentReportingOtherItemAmount · last filed 2026-08-11
- Tango Therapeutics, Inc. segment reporting other item amount for the quarter ending 2026-06-30 was $18.14M, a 96.62% increase year-over-year.
- Tango Therapeutics, Inc. segment reporting other item amount for the quarter ending 2026-03-31 was $11.98M, a 35.74% increase year-over-year.
- Tango Therapeutics, Inc. segment reporting other item amount for the quarter ending 2025-12-31 was $6.65M, a 15.31% decline year-over-year.
- Tango Therapeutics, Inc. segment reporting other item amount for the quarter ending 2025-09-30 was $7.11M, a 5.31% decline year-over-year.
- Tango Therapeutics, Inc. segment reporting other item amount for fiscal 2025 was $31.81M, a 11.81% increase from fiscal 2024.
- Tango Therapeutics, Inc. segment reporting other item amount for fiscal 2024 was $28.45M, a 23.32% increase from fiscal 2023.
- Tango Therapeutics, Inc. segment reporting other item amount for fiscal 2023 was $23.07M, a 14.95% decline from fiscal 2022.
- Tango Therapeutics, Inc. segment reporting other item amount for fiscal 2022 was $27.13M.
| Period end | Segment Reporting Other Item Amount 3 month | Segment Reporting Other Item Amount 6 month | Segment Reporting Other Item Amount 9 month | Segment Reporting Other Item Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.14M 10-Q · filed 2026-08-11 | $30.12M 10-Q · filed 2026-08-11 | $36.77M derived: sum of 3 quarters · filed 2026-08-11 | $43.88M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $11.98M 10-Q · filed 2026-05-13 | $18.63M derived: sum of 2 quarters · filed 2026-05-13 | $25.74M derived: sum of 3 quarters · filed 2026-05-13 | $34.97M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $6.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $13.76M derived: sum of 2 quarters · filed 2026-03-05 | $22.99M derived: sum of 3 quarters · filed 2026-08-11 | $31.81M 10-K · filed 2026-03-05 |
| 2025-09-30 | $7.11M 10-Q · filed 2025-11-04 | $16.34M derived: sum of 2 quarters · filed 2026-08-11 | $25.16M 10-Q · filed 2025-11-04 | $33.02M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $9.23M 10-Q · filed 2026-08-11 | $18.05M 10-Q · filed 2026-08-11 | $25.90M derived: sum of 3 quarters · filed 2026-08-11 | $33.41M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $8.83M 10-Q · filed 2026-05-13 | $16.68M derived: sum of 2 quarters · filed 2026-05-13 | $24.19M derived: sum of 3 quarters · filed 2026-05-13 | $30.96M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $7.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $15.36M derived: sum of 2 quarters · filed 2026-03-05 | $22.13M derived: sum of 3 quarters · filed 2026-03-05 | $28.45M 10-K · filed 2026-03-05 |
| 2024-09-30 | $7.51M 10-Q · filed 2025-11-04 | $14.28M derived: sum of 2 quarters · filed 2025-11-04 | $20.60M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $6.77M 10-Q · filed 2025-08-05 | $13.09M 10-Q · filed 2025-08-05 | ||
| 2024-03-31 | $6.32M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $23.07M 10-K · filed 2026-03-05 | |||
| 2022-12-31 | $27.13M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |